Ascendis Pharma A/SASNDNASDAQ
Loading
Year-over-year earnings per share growth rate
Percentile
P82
Within normal range
vs 2Y Ago
1x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 46.00% |
| Q3 2025 | -56.25% |
| Q2 2025 | 59.49% |
| Q1 2025 | -146.88% |
| Q4 2024 | 62.13% |
| Q3 2024 | 11.52% |
| Q2 2024 | 16.96% |
| Q1 2024 | -50.33% |
| Q4 2023 | 46.87% |
| Q3 2023 | -33.33% |
| Q2 2023 | -9.09% |
| Q1 2023 | 46.49% |
| Q4 2022 | -22.11% |
| Q3 2022 | -107.53% |
| Q2 2022 | 33.94% |
| Q1 2022 | -12.18% |
| Q4 2021 | -34.01% |
| Q3 2021 | 41.20% |
| Q2 2021 | -113.68% |
| Q1 2021 | 55.00% |
| Q4 2020 | -12.55% |
| Q3 2020 | -17.26% |
| Q2 2020 | -49.24% |
| Q1 2020 | 21.43% |
| Q4 2019 | -216.98% |
| Q3 2019 | 57.60% |
| Q2 2019 | -0.81% |
| Q1 2019 | -63.16% |
| Q4 2018 | 6.17% |
| Q3 2018 | -47.27% |
| Q2 2018 | 48.60% |
| Q1 2018 | -16.30% |
| Q4 2017 | 11.54% |
| Q3 2017 | -10.64% |
| Q2 2017 | -20.51% |
| Q1 2017 | -52.94% |
| Q4 2016 | 29.17% |
| Q3 2016 | -35.85% |
| Q2 2016 | 35.37% |
| Q1 2016 | -70.83% |